Use your antibodies-online credentials, if available.
抗Human ARID1A 抗体:
抗Mouse (Murine) ARID1A 抗体:
抗Rat (Rattus) ARID1A 抗体:
Human Polyclonal ARID1A Primary Antibody for ICC, IF - ABIN4281563
Bolander, Agnarsdóttir, Strömberg, Ponten, Hesselius, Uhlen, Bergqvist: The protein expression of TRP-1 and galectin-1 in cutaneous malignant melanomas. in Cancer genomics & proteomics 2009
Show all 21 Pubmed References
Human Polyclonal ARID1A Primary Antibody for WB - ABIN188644
Wurster, Precht, Pazin: NF-κB and BRG1 bind a distal regulatory element in the IL-3/GM-CSF locus. in Molecular immunology 2011
the correlation between the loss of ARID1A immunoreactivity and reduced ARID1B (显示 ARID1B 抗体) levels indicates that ARID1B (显示 ARID1B 抗体) could be an attractive target for anti-cancer therapy.
these data suggest that the combined treatment with PI3K (显示 PIK3CA 抗体) inhibitor BKM120 and PARP (显示 COL11A2 抗体) inhibitor olaparib may be a promising therapeutic regimen for the treatment of gastric cancer, and ARID1A deficiency could serve as a potential predictive therapeutic biomarker.
Although Genome-Wide Association studies have not been carried out in the field of alcohol-related hepatocellular carcinoma (HCC (显示 FAM126A 抗体)), common single nucleotide polymorphisms conferring a small increase in the risk of liver cancer risk have been identified. Specific patterns of gene mutations including CTNNB1 (显示 CTNNB1 抗体), TERT (显示 TERT 抗体), ARID1A and SMARCA2 (显示 SMARCA2 抗体) exist in alcohol-related HCC (显示 FAM126A 抗体). [review]
The authors find that ARID1A has a dominant role in maintaining chromatin accessibility at enhancers, while the contribution of ARID1B (显示 ARID1B 抗体) is evident only in the context of ARID1A mutation.
ARID1A and human epidermal growth factor receptor (显示 EGFR 抗体)-2 (Her-2 (显示 ERBB2 抗体)) status were found to be independent prognostic factors of both overall survival (OS) and disease free survival (DFS (显示 FST 抗体)).
ARID1A expression loss was associated with poor overall survival in Asians with gastric cancer. [meta-analysis]
the significant correlation was achieved between the negative ARID1A expression and the FIGO stage of endometrium-related gynecological cancers, but not the other characteristics.
This metaanalysis indicated that Gastric Cancer or Colorectal Cancer with ARID1A alteration might be a marker of poor prognosis. The ARID1A alteration of Gastric Cancer may result from different epigenetic factors.
Low ARID1A expression is associated with clear cell and endometrioid carcinoma of the ovary and the endometrium.
Loss of PTEN and ARID1A expression is highly specific for malignancy in effusion pathology
ARID1A regulates expression of SOX9, activation of the mTOR pathway, and differentiation of pancreatic ductal cells. ARID1A inhibits formation of pancreatic ductal adenocarcinomas from intraductal papillary mucinous neoplasms in mice with pancreatic expression of activated KRAS and is down-regulated in IPMN and PDAC tissues from patients.
Our results identified PIK3IP1 (显示 PIK3IP1 抗体) as a novel target of ARID1A and PGR (显示 PGR 抗体) in the murine uterus.
Mice with liver-specific homozygous or heterozygous Arid1a loss were resistant to tumor initiation while ARID1A overexpression accelerated initiation.
Loss of HDAC (显示 HDAC3 抗体)-mediated repression and gain of NF-kappaB (显示 NFKB1 抗体) activation underlie cytokine induction in ARID1A- and PIK3CA (显示 PIK3CA 抗体)-mutation-driven ovarian cancer.
ARID1A mutation inactivates the apoptosis-promoting function of p53 (显示 TP53 抗体) by upregulating HDAC6 (显示 HDAC6 抗体), indicating that pharmacological inhibition of HDAC6 (显示 HDAC6 抗体) is a therapeutic strategy for ARID1A-mutated cancers.
ARID1A normally targets SWI (显示 SMARCA1 抗体)/SNF (显示 SNRPA 抗体) complexes to enhancers.
Consistent with the latter, Arid1a reexpression in tumor cells led to increased p21 (Cdkn1a (显示 CDKN1A 抗体)) expression and dramatic accumulation of cells in G2 phase of the cell cycle. These results also indicate a potential opportunity for therapeutic intervention in ARID1A-deficient human breast cancer subtypes that retain one intact copy of the gene and also maintain wild-type TRP53 (显示 TP53 抗体) activity
The Arid1a loss reprograms chromatin to restrict promoter access by transcription factors such as C/ebpalpha (显示 CEBPA 抗体), which enforces differentiation, and E2F4 (显示 E2F4 抗体), which suppresses cell-cycle re-entry.
This study provides an alternative mechanism by which Arid1a deficiency contributes to hepatocellular carcinoma tumorigenesis.
ARID1A positively regulates Klf15 expression with PGR (显示 PGR 抗体) to inhibit epithelial proliferation at peri (显示 POSTN 抗体)-implantation. Our results suggest that Arid1a has a critical role in modulating epithelial proliferation which is a critical requisite for fertility
This gene encodes a member of the SWI/SNF family, whose members have helicase and ATPase activities and are thought to regulate transcription of certain genes by altering the chromatin structure around those genes. The encoded protein is part of the large ATP-dependent chromatin remodeling complex SNF/SWI, which is required for transcriptional activation of genes normally repressed by chromatin. It possesses at least two conserved domains that could be important for its function. First, it has a DNA-binding domain that can specifically bind an AT-rich DNA sequence known to be recognized by a SNF/SWI complex at the beta-globin locus. Second, the C-terminus of the protein can stimulate glucocorticoid receptor-dependent transcriptional activation. It is thought that the protein encoded by this gene confers specificity to the SNF/SWI complex and may recruit the complex to its targets through either protein-DNA or protein-protein interactions. Two transcript variants encoding different isoforms have been found for this gene.
ARID domain-containing protein 1A
, AT-rich interactive domain-containing protein 1A
, BRG1-associated factor 250a
, OSA1 nuclear protein
, SWI-like protein
, SWI/SNF complex protein p270
, SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily F member 1
, brain protein 120
, chromatin remodeling factor p250
, osa homolog 1
, AT rich interactive domain 1A (Swi1 like)
, BRG1-associated factor 250
, SWI-SNF complex protein p270
, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily f, member 1
, Swi1 like
, AT rich interactive domain 1A (SWI-like)
, AT-rich interactive domain-containing protein 1A-like
, AT rich interactive domain 1Aa (SWI-like)